1. A Critical Overview of the Biological Effects of Mitomycin C Application on the Cornea Following Refractive Surgery
- Author
-
Arranz-Marquez, Esther, Katsanos, Andreas, Kozobolis, Vassilios P., Konstas, Anastasios G. P., and Teus, Miguel A.
- Subjects
LASEK ,030213 general clinical medicine ,medicine.medical_specialty ,genetic structures ,PRK ,Corneal Surgery, Laser ,Ablation Techniques ,Mitomycin ,medicine.medical_treatment ,Visual Acuity ,Photoablation ,Keratomileusis ,Review ,Corneal Diseases ,Surface ablation ,Cornea ,03 medical and health sciences ,Antimitotic ,Postoperative Complications ,0302 clinical medicine ,Mitomycin C ,Ophthalmology ,Refractive surgery ,medicine ,Humans ,Pharmacology (medical) ,Corneal surface ,MMC ,Wound Healing ,Antibiotics, Antineoplastic ,business.industry ,General Medicine ,eye diseases ,Photorefractive keratectomy ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Haze ,sense organs ,business - Abstract
During the last 2 decades, modifying the shape of the cornea by means of laser photoablation has emerged as a successful and popular treatment option for refractive errors. Corneal surface ablation techniques such as photorefractive keratectomy (PRK) and laser-assisted subepithelial keratomileusis (LASEK) offer good refractive results while having a minimal impact on corneal biomechanical stability. Past limitations of these techniques included the long-term regression of refractive outcome and a vigorous healing response that reduced corneal clarity in some patients (giving rise to what is clinically described as "haze"). Mitomycin C (MMC) was introduced as a healing modulator and applied on the corneal surface after refractive surgery to address these drawbacks. This article critically reviews the available evidence on the biological effects, safety, and clinical benefits of the off-label use of MMC in corneal refractive surgery.
- Published
- 2019